-
Uncategorized1 month agoSTAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
WASHINGTON — Food and Drug Administration Commissioner Marty Makary is resigning from his role, according to an administration source familiar with the matter. Kyle Diamantas, the...
-
Uncategorized1 month ago
FDA Commissioner Makary to resign, source says
FDA Commissioner Marty Makary is set to resign after his job status hung in the balance for days. A source familiar with the commissioner’s thinking told...
-
Uncategorized1 month ago
What I learned at a journalism fellowship about covering healthcare AI
Last week, I was reminded that reporting on AI in healthcare requires continuous scrutiny of the incentives that drive it. Thanks to a fellowship hosted by...
-
Uncategorized1 month agoSupreme Court extends mifepristone deadline
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. My co-workers and pals Isabella Cueto...
-
Uncategorized1 month ago
Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis
Kyverna Therapeutics has officially started a rolling submission to the FDA for miv-cel as the company conducts additional natural history analysis at the agency’s request, keeping...
-
Uncategorized1 month ago
Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
-
Uncategorized1 month ago
Pfizer and Arvinas give disappointing breast cancer drug to Rigel
Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer...
-
Uncategorized1 month agoSTAT+: STAT examines America’s deadliest drug
“Under-babied.” Dr. Oz said that’s the name for a condition that affects one-in-three Americans. I guess that means over-babied is the condition of having too many...
-
Uncategorized1 month ago
Bayer to make ‘careful but aggressive’ return to pharma M&A, CEO says
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but...
-
Uncategorized1 month ago
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
